Business
Oncology Pharma, Inc. Narrows Focus on Funding Efforts
Oncology Pharma, Inc. Narrows Focus on Funding Efforts.
About this update from Oncology Pharma Inc.
[{"type":"text","content":"\n San Francisco, CA, Jan. 28, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTCPK: ONPH) would like to inform investors that it has completed its relationship with Tulynode Biosciences, Inc., and will be focusing on anti-cancer drugs instead of medical devices.  Oncology Pharma wishes Tulynode Biosciences success.   Oncology Pharma is currently focusing all efforts on obtaining funding for Kalos Therapeutics, NanoSmart® Pharmaceuticals Inc., Diagnomics, Inc. and Ribera Solutions.  Due diligence is currently underway for the funding LOI previously announced and the Company expects to issue more updates as they become available. ABOUT ONCOLOGY PHARMA, INC. ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the \"Company\") the Company is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare. FORWARD LOOKING STATEMENTS Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and m...